Trials / Terminated
TerminatedNCT01741142
Efficacy and Safety Study of ABT-436 in Major Depressive Disorder
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of ABT-436 in Major Depressive Disorder
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- AbbVie (prior sponsor, Abbott) · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose is to study the efficacy and safety of ABT-436 in Major Depressive Disorder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-436 | Subjects receiving ABT-436 |
| DRUG | Escitalopram | Subjects receiving escitalopram |
| DRUG | Placebo | Subject receiving placebo |
Timeline
- Start date
- 2012-01-01
- Primary completion
- 2013-10-01
- Completion
- 2015-08-01
- First posted
- 2012-12-04
- Last updated
- 2013-10-08
Locations
18 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01741142. Inclusion in this directory is not an endorsement.